Literature DB >> 18208503

Negative impact of metabolic syndrome on the responsiveness to sildenafil in Japanese men.

Takahiro Suetomi1, Koji Kawai, Shiro Hinotsu, Akira Joraku, Takehiro Oikawa, Noritoshi Sekido, Naoto Miyanaga, Toru Shimazui, Hideyuki Akaza.   

Abstract

INTRODUCTION: Several recent studies suggested that the prevalence of erectile dysfunction (ED) was higher in men with metabolic syndrome (MS). AIM: We analyzed the impact of MS on the responsiveness to sildenafil.
METHODS: A total of 133 ED patients were evaluated for the prevalence of MS and graded on severity of ED. MS was diagnosed according to the International Diabetes Federation (IDF) definition. The severity of ED was evaluated by the International Index of Erectile Function (IIEF) questionnaire. Hormonal parameters were measured for all patients, and the IIEF questionnaire was conducted after administration of eight tablets of 50-mg doses of sildenafil. If the scores to questions 3 and 4 of the IIEF were 4 or higher after administration, the patients were defined as responders to sildenafil. MAIN OUTCOME MEASURES: To clarify the negative impact of MS on the responsiveness to sildenafil.
RESULTS: The mean age of the patients was 56.9 years, and 25 patients were diagnosed with MS. The IIEF-erectile function score and the response rate for sildenafil decreased as the number of MS components increased. Logistic regression analysis showed that the presence of MS along with severity of ED and history of pelvic surgery were significant independent risk factors of nonresponse for sildenafil. The hazard ratio for the presence of MS was 3.30 (95% confidence interval [CI]: 1.17-9.73). No meaningful association was observed between total testosterone or free testosterone levels and MS in this population.
CONCLUSION: We demonstrated the negative impact of MS on the responsiveness to sildenafil. Erectile function and response rate for sildenafil decreased as the number of MS components increased.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18208503     DOI: 10.1111/j.1743-6109.2007.00747.x

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  4 in total

1.  Treatment Strategy for Non-Responders to PDE5 Inhibitors.

Authors:  Nam Cheol Park; Tae Nam Kim; Hyun Jun Park
Journal:  World J Mens Health       Date:  2013-04-23       Impact factor: 5.400

2.  Degree of Planning of Sexual Intercourse Among Men From China, Japan, and Taiwan Taking Medication for Erectile Dysfunction: Findings of an Observational, Cross-Sectional Survey.

Authors:  Bang-Ping Jiann; Koichi Nakajima; Sonali Dighe; Chad D Harshman-Smith; Tarek A Hassan
Journal:  Sex Med       Date:  2018-12-03       Impact factor: 2.491

3.  The SIAMS-ED Trial: A National, Independent, Multicentre Study on Cardiometabolic and Hormonal Impairment of Men with Erectile Dysfunction Treated with Vardenafil.

Authors:  Andrea M Isidori; Giovanni Corona; Antonio Aversa; Daniele Gianfrilli; Emmanuele A Jannini; Carlo Foresta; Mario Maggi; Andrea Lenzi
Journal:  Int J Endocrinol       Date:  2014-05-15       Impact factor: 3.257

4.  Establishment of NOAEL for intracavernous injections of human bone marrow-derived mesenchymal stem cells in rats.

Authors:  Jong Keun Kim; Myoung Jin Jang; Bo Hyun Kim; Ki Ryung Choi; Geehyun Song; Ha Chul Shin; Nayoung Suh; Yong Man Kim; Dalsan You; Tai Young Ahn; Choung-Soo Kim
Journal:  Investig Clin Urol       Date:  2019-12-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.